Literature DB >> 18207193

Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors.

Ming Yin1, Sheldon Bastacky, Uma Chandran, Michael J Becich, Rajiv Dhir.   

Abstract

PURPOSE: The incidence of prostate cancer has surged dramatically in recent years due to improved cancer screening and detection mechanisms. There has also been significant interest specifically pertaining to the increased incidence of prostate cancer in younger males, which might be due to increased screening. We analyzed our data set of incidental prostate cancer, derived from a project accruing prostate tissues for research from normal organ donors, who are a predominantly white population.
MATERIALS AND METHODS: Information about any prior prostate cancer screening in this cohort was not available. In addition, this population had no history of intervention related to benign or malignant prostate disease. The case cohort consisted of 340 prostates harvested for research from organ donors who died suddenly from August 1994 to April 2007. Stroke, motor vehicle accident, homicidal and suicidal gunshot wound to the head, cardiorespiratory arrest and trauma accounted for more than 90% of the causes of death in donors.
RESULTS: Evaluation of serially sectioned prostate tissues revealed adenocarcinoma with or without high grade prostate intraepithelial neoplasia in 12% of cases. High grade prostate intraepithelial neoplasia alone occurred in 10.6% of donors. There was an age dependent increase in high grade prostate intraepithelial neoplasia starting from the 4th decade of life. Prostate adenocarcinoma escalated from the 5th decade and thereafter with a 1 in 3 chance of carrying incidental cancer in the 60 to 69-year-old age group and with 46% of 70 to 81-year-old men harboring prostate cancer.
CONCLUSIONS: This study provides insight into the prevalence of prostate adenocarcinoma and high grade prostate intraepithelial neoplasia in the general healthy population. Associated issues, such as the age at which to start screening for prostate cancer and donor transmitted malignancy, were also discussed.

Entities:  

Mesh:

Year:  2008        PMID: 18207193     DOI: 10.1016/j.juro.2007.10.057

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  31 in total

Review 1.  The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer.

Authors:  Bulent Cetin; Ahmet Ozet
Journal:  Curr Urol       Date:  2019-10-01

Review 2.  Controversies associated with the evaluation of elderly men with localized prostate cancer when considering radical prostatectomy.

Authors:  Koji Mitsuzuka; Yoichi Arai
Journal:  Int J Clin Oncol       Date:  2014-08-26       Impact factor: 3.402

3.  Conceptualizing overdiagnosis in cancer screening.

Authors:  Pamela M Marcus; Philip C Prorok; Anthony B Miller; Emily J DeVoto; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

4.  Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries.

Authors:  Yi-Ping Zhu; Ding-Wei Ye; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Hai-Liang Zhang; Yi-Jun Shen; Yao Zhu; Guo-Hai Shi
Journal:  Asian J Androl       Date:  2008-12-01       Impact factor: 3.285

5.  Active surveillance for low-risk prostate cancer: diversity of practice across Europe.

Authors:  A Azmi; R A Dillon; S Borghesi; M Dunne; R E Power; L Marignol; B D P O'Neill
Journal:  Ir J Med Sci       Date:  2014-03-21       Impact factor: 1.568

Review 6.  A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review.

Authors:  Chunming Gong; Xueying Hu; Yong Gao; Yunfei Cao; Feng Gao; Zengnan Mo
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

7.  Prostate cancer screening: Canadian guidelines 2011.

Authors:  Jonathan I Izawa; Laurence Klotz; D Robert Siemens; Wassim Kassouf; Alan So; John Jordan; Michael Chetner; Alla E Iansavichene
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 8.  Metabolic alterations and targeted therapies in prostate cancer.

Authors:  Richard Flavin; Giorgia Zadra; Massimo Loda
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

Review 9.  [How to use PSA in 2009].

Authors:  Anton Ponholzer; Franz Stoiber; Wolfgang Loidl; Michael Rauchenwald; Paul Schramek; Stephan Madersbacher
Journal:  Wien Med Wochenschr       Date:  2009

10.  Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.

Authors:  Signe Benzon Larsen; Klaus Brasso; Peter Iversen; Jane Christensen; Michael Christiansen; Sigrid Carlsson; Hans Lilja; Søren Friis; Anne Tjønneland; Susanne Oksbjerg Dalton
Journal:  Eur J Cancer       Date:  2013-05-17       Impact factor: 9.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.